The treatment of multiple sclerosis (MS) falls into 3 categories: treatment of exacerbations,
slowing disease progression with disease-modifying therapies (DMTs), and symptomatic …

Multiple sclerosis (MS) is a chronic immunemediated disease that potentially requires
symptomatic and disease-modifying therapies. Numerous symptoms (eg, fatigue, spasticity …

Multiple sclerosis (MS) is a presumed autoimmune disorder of the central nervous system,
resulting in inflammatory demyelination and axonal and neuronal injury. New diagnostic …

Multiple sclerosis (MS) is a chronic inflammatory demyelinating central nervous system
disease that typically strikes young adults, especially women. The pathobiology of MS …

Multiple sclerosis (MS) is primarily an autoimmune disease of the central nervous system,
but also encompasses prominent neurodegenerative aspects. A significant proportion of MS …

Results from registry studies can provide valuable information about the prevalence and
clinical course of different forms of multiple sclerosis (MS). Such studies can also help …

Currently, several disease-modifying therapies for the treatment of multiple sclerosis are
established and more are likely to be introduced. These treatment options differ with respect …

Several disease‐modifying drugs (DMDs) are currently approved for the treatment of
multiple sclerosis (MS). Recently, there has been increased identification and development …

Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous
system (CNS). It predominantly affects young women and is one of the most common causes …

The treatment era for multiple sclerosis began in 1993 with the approval of the first disease‐
modifying therapy. This changed the management of multiple sclerosis from treating acute …